Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Citalopram is a selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitor (SSRI) which has been evaluated primarily in the treatment of major depression. In well controlled short term studies, Citalopram had efficacy similar to that of a number of but not all, tricyclic or tetracyclic antidepressants and was as effective as fluoxetine and fluvoxamine. There is some evidence of a faster onset of action for Citalopram compared with fluoxetine. Initial data suggest that Citalopram is effective in the prevention of depressive relapse and in the treatment of post-stroke depression.
The anticholinergic and cardiovascular adverse events often seen with tricyclic antidepressants generally occur less frequently or are infrequent with Citalopram, as with other SSRIs. Citalopram has been well tolerated in the elderly and in patients with existing cardiovascular disease. In vitro and in vivo pharmacodynamic studies suggest that Citalopram is a weak inhibitor of cytochrome P450 (CYP) 2D6, and data from several interaction studies in patients and healthy volunteers are consistent with this finding.
Thus, Citalopram is an effective and well tolerated SSRI which, like the other members of its class, represents a suitable first-line therapy for major depression. Additional efficacy data would be beneficial in clarifying the potential of Citalopram in the elderly and in patients with post-stroke depression or preexisting cardiovascular disorders, for whom anticholinergic or cardiovascular adverse events (caused by tricyclic antidepressants) are a serious concern. The main distinguishing feature of Citalopram within its class is its apparent low propensity to cause problematic drug interactions with CYP2D6 substrates; these include a number of commonly prescribed drug classes, such as antipsychotics, tricyclic antidepressants, antiarrhythmics and β-blockers. Thus, Citalopram may prove useful in the many patients with depression who require one or more such agents for treatment of additional psychiatric or general disorders.
Citalopram is a potent in vitro inhibitor of serotonin (5-hydroxytryptamine; 5-HT) uptake. Its activity in this respect is more than 3000 times greater than that against noradrenaline (norepinephrine) uptake, making it the most serotonin-selective agent in its class. Citalopram has low affinity in vitro for adrenergic, muscarinic, dopaminergic and serotonergic receptors. Evidence from behavioural studies in animals supports a selective facilitatory effect of Citalopram on serotonergic neurotransmission.
Citalopram is a weaker in vitro and in vivo inhibitor of the hepatic cytochrome P450 (CYP) 2D6 isozyme than paroxetine and fluoxetine and therefore has a lower potential for pharmacokinetic interactions with cytochrome CYP2D6 substrates such as tricyclic antidepressants and antipsychotic agents.
Peak plasma concentrations of Citalopram are observed 2 to 4 hours after single or multiple oral doses and steady-state plasma concentrations are reached after about 1 week of daily administration. The plasma concentration-dose relationship for Citalopram is linear for doses of 10 to 60mg.
Citalopram is converted by hepatic CYP isozymes to the metabolites demethyl- and didemethyl-citalopram which are less lipophilic than the parent molecule (and are weaker serotonin reuptake inhibitors).
Preliminary indications suggest that Citalopram may cause only moderate pharmacokinetic interactions or have no effect when coadministered with tricyclic antidepressants which are metabolised by CYP2D6, although formal studies of such interactions are limited. Available data suggest that coadministration of Citalopram and antipsychotic agents does not cause any significant pharmacokinetic interactions.
The elimination half-life of Citalopram following oral administration is about 30 hours, with an estimated clearance of 26 to 28 L/h. Approximately 12% of an oral dose of Citalopram is excreted unchanged into the urine.
Aging appears to be associated with increased plasma concentrations and decreased clearance of Citalopram. Similar effects are seen in patients with renal or hepatic dysfunction.
In well controlled clinical studies, score reductions for the Hamilton Depression Rating Scale (HDRS) or Montgomery-Åsberg Depression Rating Scale (MADRS) ranged from about 43 to 81% with Citalopram and from about 56 to 71 % with tricyclic or tetracyclic antidepressants. In the largest comparative study published to date, reductions in HDRS scores after 6 weeks were similar for Citalopram and imipramine in more than 400 patients from general practice. Furthermore, the proportions of patients whose HDRS score was reduced by ≥50% were similar for Citalopram and imipramine. In smaller studies, Citalopram had end-point efficacy similar to that of amitriptyline or maprotiline (2 studies each), although comparisons with mianserin have produced somewhat contradictory findings. Citalopram was less effective than clomipramine in a single study. Results from meta-analyses indicate that Citalopram is broadly similar to tricyclic agents (amitriptyline, clomipramine, nortriptyline and imipramine) in its antidepressant efficacy in clinical trials.
Citalopram had overall efficacy similar to that of fluoxetine in general practice patients and in psychiatrie inpatients and outpatients. However, analysis of 3 different clinical parameters after 2 weeks indicated that the effects of Citalopram were achieved significantly faster than those of fluoxetine in the general practice study; no significant difference between the two treatment groups was apparent at subsequent timepoints. A comparison of Citalopram with fluvoxamine in patients with major depression demonstrated equivalent efficacy for the 2 drugs.
Data from clinical trials and meta-analyses suggest that nausea and vomiting (20% incidence in a meta-analysis of 746 patients), increased sweating, dry mouth and headache were the most common adverse events experienced by Citalopram recipients. The anticholinergic and cardiovascular adverse events often seen with tricyclic antidepressants (dry mouth, constipation, tachycardia, orthostatic hypotension) appear to occur less frequently or to be infrequent with Citalopram in most large studies. Data from 2 comparative studies suggest that there are no major differences in tolerability between Citalopram and fluoxetine, although vomiting during the first week of treatment was significantly more common in Citalopram recipients (3.8%) than in fluoxetine recipients (0%) in one study (the Citalopram dosage in this trial was twice that recommended for initial treatment). Nausea and diarrhoea were significantly more common in patients receiving fluvoxamine 100 to 200 mg/day than in those receiving Citalopram 20 to 40 mg/day in a single study (the starting dosage of fluvoxamine was twice that normally recommended). This difference was apparent at all timepoints for nausea, but had disappeared by week 6 for diarrhoea.
Clinical and postmarketing experience with Citalopram suggests that it is not associated with serious cardiovascular toxicity, and is well tolerated in patients with existing cardiovascular conditions, in those who are receiving drugs that may cause ECG abnormalities and in the elderly. Like the other SSRIs, Citalopram appears to be less toxic than tricyclic antidepressants when taken in overdose during suicide attempts.
Dosage and Administration
The recommended oral treatment regimen for Citalopram in depressed patients is 20 to 60mg once daily, titrated to therapeutic effect, with a minimum treatment period of 6 months to prevent relapse. Citalopram 20 to 30mg once daily is currently recommended for elderly patients. Dosage adjustments are not necessary in patients with mild or moderate renal impairment; information on the use of Citalopram in patients with severe renal dysfunction is lacking. Citalopram 20 to 30mg is recommended as the maximum dose in patients with impaired hepatic function. Citalopram should not be given to patients who are taking monoamine oxidase inhibitors.
- Wade, A.G., Lepola, U., Koponen, H.J. (1997) The effect of Citalopram in panic disorder. Br J Psychiatry 170: pp. 549-53
- Lepola, U., Leinonen, E., Turtonen, J. (1993) The effect of Citalopram in panic disorder and agoraphobia: a pilot study [abstract]. Psychopharmacology 111: pp. B7
- Humble, M., Wistedt, B. (1992) Serotonin, panic disorder and agoraphobia: short-term and long-term efficacy of Citalopram in panic disorders. Int Clin Psychopharmacol 6: pp. 21-39
- Nyth, A.L., Gottfries, C.G. (1990) The clinical efficacy of Citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 157: pp. 894-901
- Vartiainen, H., Tiihonen, J., Putkonen, A. (1995) Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 91: pp. 348-51
- Andersen, G., Vestergaard, K., Rils, J.O. (1993) Citalopram for post-stroke pathological crying. Lancet 342: pp. 837-9
- Hyttel, J., Bogeso, K.P., Perregaard, J. (1992) The pharmacological effect of Citalopram resides in the (S)-(+)-enantiomer. J Neural Transm Gen Sect 88: pp. 157-60
- Goodwin, G.M. (1996) How do antidepressants affect serotonin receptors? The role of serotonin receptors in the therapeutic and side effect profile of the SSRIs. J Clin Psychiatry 57: pp. 9-13
- Moret, C., Briley, M. (1996) Effects of acute and repeated administration of Citalopram on extracellular levels of serotonin in rat brain. Eur J Pharmacol 295: pp. 189-97
- Auerbach, S.B., Hjorth, S. (1995) Effect of chronic administration of the selective serotonin (5-HT) uptake inhibitor Citalopram on extracellular 5-HT and apparent autoreceptor sensitivity in rat forebrain in vivo. Naunyn Schmiedebergs Arch Pharmacol 352: pp. 597-606
- Arborelius, L., Nomikos, G.G., Hertel, P. (1996) The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic treatment with Citalopram. Naunyn Schmiedebergs Arch Pharmacol 353: pp. 630-40
- Hjorth, S., Auerbach, S.B. (1996) 5-HT1A autoreceptors and the mode of action of selective serotonin reuptake inhibitors (SSRI). Behav Brain Res 73: pp. 281-3
- Arborelius, L., Nomikos, G.G., Grillner, P. (1995) 5-HT1A receptor antagonists increase the activity of serotonergic cells in the dorsal raphe nucleus in rats treated acutely or chronically with Citalopram. Naunyn Schmiedebergs Arch Pharmacol 352: pp. 157-65
- Milne, R.J., Goa, K.L. (1991) Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 41: pp. 450-77
- Hyttel, J. (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9: pp. 19-26
- Richelson, E., Pfenning, M. (1984) Blockade by antidepressants and related compounds of biogenic amine uptake into rat brain synaptosomes: most antidepressants selectively block norepinephrine uptake. Eur J Pharmacol 104: pp. 277-86
- Hyttel, J. (1982) Citalopram — pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 6: pp. 277-95
- Richelson, M., Nelson, A. (1984) Antagonism by antidepressants of neurotransmitter receptors of normal human brain in vitro. J Pharmacol Exp Ther 230: pp. 94-102
- Hall, H., Sallemark, M., Wedel, I. (1984) Acute effects of atypical antidepressants on various receptors in the rat brain. Acta Pharmacol Toxicol Copenh 54: pp. 379-84
- Hyttel, J., Arnt, J., Sánchez, C. (1995) The pharmacology of Citalopram. Rev Contemp Pharmacother 6: pp. 271-85
- Hyttel, J., Overø, K.F., Arnt, J. (1984) Biochemical effects and drug levels in rats after long-term treatment with the specific 5-HT-up-take inhibitor, Citalopram. Psychopharmacology (Berl) 83: pp. 20-7
- Garcha, G., Smokcum, R.W., Stephenson, J.D. (1985) Effects of some atypical antidepressants on β-adrenoceptor binding and adenylate cyclase activity in the rat forebrain. Eur J Pharmacol 108: pp. 1-7
- Luo, H., Richardson, J.S. (1993) A pharmacological comparison of Citalopram, a bicyclic serotonin selective uptake inhibitor, with traditional tricyclic antidepressants. Int Clin Psychopharmacol 8: pp. 3-12
- Vetulani, J., Antkiewicz-Michaluk, L., Rokosz-Pelc, A. (1984) Chronic administration of antidepressant drugs increases the density of cortical [3H]prazosin binding sites in the rat. Brain Res 310: pp. 360-2
- Gobbi, M., Crespi, D., Foddi, M.C. (1997) Effects of chronic treatment with fluoxetine and Citalopram on 5-HT uptake, 5-HT1B autoreceptors, 5-HT3 and 5-HT4 receptors in rats. Naunyn Schmiedebergs Arch Pharmacol 356: pp. 22-8
- Tiihonen, J., Kuoppamäki, M., Någren, K. (1996) Serotonergic modulation of striatal D2 dopamine receptor binding in humans measured with positron emission tomography. Psychopharmacology 126: pp. 277-80
- Christensen, A.V., Fjalland, B., Pedersen, V. (1977) Pharmacology of a new phthalane (Lu 10-171), with specific 5-HT uptake inhibiting properties. Eur J Pharmacol 41: pp. 153-62
- Fairweather, D.B., Dal Pozzo, C., Kerr, J.S. (1997) Citalopram compared to dothiepin and placebo: effects on cognitive function and psychomotor performance. Hum Psychopharmacol 12: pp. 119-26
- Sindrup, S.H., Brøsen, K., Hansen, M.G. (1993) Pharmacokinetics of Citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 15: pp. 11-7
- Crewe, H.K., Lennard, M.S., Tucker, G.T. (1992) The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 34: pp. 262-5
- Skjelbo, E., Brosen, K. (1992) Inhibitors of imipramine metabolism by human liver microsomes. Br J Clin Pharmacol 34: pp. 256-61
- Jeppesen, U., Gram, L.F., Vistisen, K. (1996) Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by Citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 51: pp. 73-8
- Priskorn, M., Larsen, F., Segonzac, A. (1997) Pharmacokinetic interaction study of Citalopram and Cimetidine in healthy subjects. Eur J Clin Pharmacol 52: pp. 241-2
- Kragh-Sørensen, P., Overø, K.F., Petersen, O.L. (1981) The kinetics of Citalopram: single and multiple dose studies in man. Acta Pharmacol Toxicol Copenh 48: pp. 53-60
- Citalopram Product Monograph, H. Lundbeck A/S, 1994
- Overø, K.F. (1978) Preliminary studies of the kinetics of Citalopram in man. Eur J Clin Pharmacol 14: pp. 69-73
- Wilde, J., Mertens, C., Overø, K.F. (1985) Citalopram versus mianserin: a controlled, double-blind trial in depressed patients. Acta Psychiatr Scand 72: pp. 89-96
- Bouchard, J.M., Delaunay, J., Delisle, J.P. (1987) Citalopram versus maprotiline: a controlled, clinical multicentre trial in depressed patients. Acta Psychiatr Scand 76: pp. 583-92
- Gravem, A., Amthor, K.F., Astrup, C. (1987) A double-blind comparison of Citalopram (Lu 10-171) and amitriptyline in depressed patients. Acta Psychiatr Scand 75: pp. 478-86
- Ahlfors, U.G., Elovaara, S., Harma, P. (1988) Clinical multicentre study of Citalopram compared double-blindly with mianserin in depressed patients in Finland. Nord Psykiatr Tidsskr 42: pp. 201-10
- Overø, K.F. (1982) Kinetics of Citalopram in man; plasma levels in patients. Prog Neuropsychopharmacol Biol Psychiatry 6: pp. 311-8
- Bjerkenstedt, L., Flyckt, L., Overø, K.F. (1985) Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with Citalopram: a double-blind comparison of three dose levels. Eur J Clin Pharmacol 28: pp. 553-7
- Baumann, P., Larsen, F. (1995) The pharmacokinetics of Citalopram. Rev Contemp Pharmacother 6: pp. 287-95
- Leinonen, E., Lepola, U., Koponen, H. (1996) The effect of age and concomitant treatment with other psychoactive drugs on serum concentrations of Citalopram measured with a non-enantioselective method. Ther Drug Monit 18: pp. 111-7
- Rochat, B., Amey, Y., Baumann, P. (1995) Analysis of enantiomers of Citalopram and its demethylated metabolites in plasma of depressive patients using chiral reverse-phase liquid chromatography. Ther Drug Monit 17: pp. 273-9
- Rochat, B., Amey, H., Gelderen, H. (1995) Determination of the enantiomers of Citalopram, its demethylated and propionic acid metabolites in human plasma by chiral HPLC. Chirality 7: pp. 389-95
- Kobayashi, K., Yamamoto, T., Chiba, K. (1995) The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 40: pp. 481-5
- Kobayashi, K., Chiba, K., Yagi, T. (1997) Identification of cytochrome P450 isoforms involved in Citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 280: pp. 927-33
- Rudorfer, M.V., Potter, W.Z. Pharmacokinetics of antidepressants. In: Meltzer, H.Y. eds. (1987) Psychopharmacology: the third generation of progress. Raven Press, New York, pp. 1353-63
- Øyehaug, E., Østensen, E.T., Salvesen, B. (1984) High-performance liquid chromatographic determination of Citalopram and four of its metabolites in plasma and urine samples from psychiatric patients. J Chromatogr 308: pp. 199-208
- Overø, K.F., Toft, B., Christophersen, L. (1985) Kinetics of Citalopram in elderly patients. Psychopharmacology 86: pp. 253-7
- Foglia, J.P., Pollock, B.G., Kirshner, M.A. (1997) Psychopharmacology in geriatric populations. Psychopharmacol Bull 33: pp. 109-12
- Syvälahti, E.K.G., Taiminen, T., Saarijärvi, S. (1997) Citalopram causes no significnt alterations in plasma neuroleptic levels in schizophrenic patients. J Int Med Res 25: pp. 24-32
- Baettig, D., Bondolfi, G., Montaldi, S. (1993) Tricyclic antidepressant plasma levels after augmentation with Citalopram: a case study. Eur J Clin Pharmacol 44: pp. 403-5
- Gram, L.F., Hansen, M.G.J., Sindrup, S.H. (1993) Citalopram: interaction studies with levomepromazine, imipramine, and lithium. Ther Drug Monit 15: pp. 18-24
- Bondolfi, G., Chautems, C., Rochat, B. (1996) Non-response to Citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation. Psycho-pharmacology 128: pp. 421-5
- Priskhorn, M., Sidhu, J.S., Larsen, F. (1997) Investigation of multiple dose Citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin. Br J Clin Pharmacol 44: pp. 199-202
- Hamilton, M. (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: pp. 278-96
- Montgomery, S.A., Åsberg, M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134: pp. 382-9
- Guy, W. eds. (1976) ECDEU assessment manual for psychopharmacology. Clinical Global Impressions (028-CGI). USGPO, Washington, DC
- Feighner, J., Overø, K., Fieve, R. (1997) Fixed dose comparison of Citalopram versus placebo in the treatment of outpatients with moderate to severe depression [poster no. 419].
- Mendels, J., Overø, K., Kiev, A. (1997) Citalopram versus placebo in the treatment of outpatients with moderate to severe depression [poster no. 465].
- Andersen, G., Vestergaard, K., Lauritzen, L. (1994) Effective treatment of poststroke depression with the selective serotonin reuptake inhibitor Citalopram. Stroke 25: pp. 1099-104
- Montgomery, S.A., Rasmussen, J.G.C., Lyby, K. (1992) Dose response relationship of Citalopram 20mg, Citalopram 40mg and placebo in the treatment of moderate and severe depression. Int Clin Psychopharmacol 6: pp. 65-70
- Nyth, A.L., Gottfries, C.G., Lyby, K. (1992) A controlled multicenter clinical study of Citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86: pp. 138-45
- Bech, P., Cialdella, P. (1992) Citalopram in depression — meta-analysis of intended and unintended effects. Int Clin Psychopharmacol 6: pp. 45-54
- Montgomery, S.A., Pedersen, V., Tanghøj, P. (1994) The optimal dosing regimen for Citalopram — a meta-analysis of nine placebo-controlled studies. Int Clin Psychopharmacol 9: pp. 35-40
- Baumann, P., Nil, R., Souche, A. (1996) A double-blind, placebocontrolled study of Citalopram with and without lithium in the treatment of therapy-resistant depressive patients: a clinical, pharmacokinetic, and pharmacogenetic investigation. J Clin Psychopharmacol 16: pp. 307-14
- Montgomery, S.A., Rasmussen, J.G., Tanghoj, P. (1993) A 24-week study of 20mg Citalopram, 40mg Citalopram, and placebo in the prevention of relapse of major depression. Int Clin Psychopharmacol 8: pp. 181-8
- Robert, P., Montgomery, S.A. (1995) Citalopram in doses of 20-60mg is effective in depression relapse prevention: a placebo-controlled 6 month study. Int Clin Psychopharmacol 10: pp. 29-35
- Shaw, D.M., Thomas, D.R., Briscoe, M.H. (1986) A comparison of the antidepressant action of Citalopram and amitriptyline. Br J Psychiatry 149: pp. 515-7
- Citalopram: clinical effect profile in comparison with clomipramine: a controlled multicenter study. Psychopharmacology 90: pp. 131-8
- Rosenberg, C., Damsbo, N., Fuglum, E. (1994) Citalopram and imipramine in the treatment of depressive patients in general practice: a Nordic multicentre clinical study. Int Clin Psychopharmacol 9: pp. 41-8
- Timmerman, L., Beurs, P., Tan, B.K. (1987) A double-blind comparative clinical trial of Citalopram vs maprotiline in hospitalized depressed patients. Int Clin Psychopharmacol 2: pp. 239-53
- Anderson, I.M., Tomenson, B.M. (1994) The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 8: pp. 238-49
- Nuijten, M.J.C., Hardens, M., Souêtre, E. (1995) A Markov process analysis comparing the cost effectiveness of maintenance therapy with Citalopram versus standard therapy in major depression. Pharmacoeconomics 8: pp. 159-68
- Patris, M., Bouchard, J.-M., Bougerol, T. (1996) Citalopram versus fluoxetine: a double-blind, controlled, multicentre, phase III trial in patients with unipolar depression treated in general practice. Int Clin Psychopharmacol 11: pp. 129-36
- Bougerol T, Scotto J-C, Patris M, et al. Citalopram and fluoxetine in major depression: comparison of two clinical trials in a psychiatrist setting and in general practice. Clin Drug Invest. In press
- Haffmans, P.M.J., Timmerman, L., Hoogduin, C.A.L. (1996) Efficacy and tolerability of Citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. Int Clin Psychopharmacol 11: pp. 157-64
- Dencker, S.J., Petersen, H.E.H. (1988) Side-effect profile of Citalopram and reference antidepressants in depression.
- Baldwin, D., Johnson, F.N. (1995) Tolerability and safety of Citalopram. Rev Contemp Pharmacother 6: pp. 315-25
- Rudorfer, M.V., Manji, H.K., Potter, W.Z. (1994) Comparative tolerability profiles of the newer versus older antidepressants. Drug Saf 10: pp. 18-46
- Lauerma, H. (1996) Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand 93: pp. 69-70
- Michael, A., Herrod, J.J. (1997) Citalopram-induced decreased libido [letter]. Br J Psychiatry 171: pp. 90
- Berk, M., Acton, M. (1997) Citalopram-associated clitoral priapasm: a case series. Int Clin Psychopharmacol 12: pp. 121-2
- Bouwer, C.D., Harvey, B.H. (1996) Phasic craving for carbohydrate observed with Citalopram. Int Clin Psychopharmacol 11: pp. 273-8
- Risby, E., Donnigan, D., Nemeroff, C. (1997) Pharmacotherapeutic considerations for psychiatric disorders: depression. Formulary 32: pp. 46-59
- Øström, M., Erikkson, A., Thorson, J. (1996) Fatal overdose with Citalopram [letter]. Lancet 348: pp. 339-40
- Grundemar, L., Wohlfart, B., Lagerstedt, C. (1997) Symptoms and signs of severe Citalopram overdose. Lancet 349: pp. 1602
- Personne, M., Persson, H., Sjöberg, G. (1997) Citalopram toxicity [letter]. Lancet 350: pp. 518-9
- Neuvonen, P.J., Pohjola-Sintonen, S., Tacke, U. (1993) Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 342: pp. 1419
- Greenberg, P.E., Stiglin, L.E., Finkelstein, S.N. (1993) The economic burden of depression in 1990. J Clin Psychiatry 54: pp. 405-18
- Kessler, R.C., McGonagle, K.A., Zhao, S. (1994) Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch Gen Psychiatry 51: pp. 8-19
- Broadhead, W.E., Blazer, D.G., George, L.K. (1990) Depression, disability days, and days lost from work in a prospective epidemiological survey. JAMA 264: pp. 2524-8
- Kupfer, D.J. (1991) Long-term treatment of depression. J Clin Psychiatry 52: pp. 28-34
- Hirschfeld, R.M.A. (1996) Long-term drug treatment of unipolar depression. Int Clin Psychopharmacol 11: pp. 211-7
- Cohen, L.J. (1997) Rational drug use in the treatment of depression. Pharmacotherapy 17: pp. 45-61
- Sussman, N., Stahl, S. (1996) Update in the pharmacotherapy of depression. Am J Med 101: pp. 26S-36S
- Jonghe, F., Swinkels, J. (1997) Selective serotonin reuptake inhibitors: relevance of differences in their pharmacological and clinical profiles. CNS Drugs 7: pp. 452-67
- Berg, S.J. (1995) Comparing SSRIs: from chemistry to clinical choice. Hum Psychopharmacol 10: pp. S199-209
- Harten, J. (1993) Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 24: pp. 203-20
- Baumann, P., Rochat, B. (1995) Comparative pharmacokinetics of selective serotonin reuptake inhibitors: a look behind the mirror. Int Clin Psychopharmacol 10: pp. 15-21
- Brøsen, K. (1993) The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Investig 71: pp. 1002-9
Volume 8, Issue 5 , pp 410-431
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors